ArticleInfection2025
Post-COVID-19-pandemic changes and clinical characteristics of invasive group a streptococcal infections from 2015 to 2023.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Promoting expertise knowledge sharing in paediatric virology: An update (Review).Experimental and therapeutic medicine · 2026Review
- Clinical predictors, microbiological profile, and outcomes of bacteremia in patients with cellulitis: a 6-year retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Observational
- Anti-Streptococcal Activity of β-Thujaplicin and Its Effect on Natural Low-Level Resistance ofPathogens (Basel, Switzerland) · 2026Article
- Epidemiological trends of invasive Streptococcus pyogenes infections in Catalonia, 2022-2024: a two-year analysis.Infection · 2026Article
- Lumbar puncture use and antibiotic treatment in newly admitted febrile children following index cases of invasive infections.BMC infectious diseases · 2026Article
- Development of a Novel Polyleucine-Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Septic complications of head and neck infections as emerging conditions in the post-COVID-19 era: an epidemiological study in a pediatric care center in Sicily.Italian journal of pediatrics · 2025Article
- Evidence for early circulation of the M1UK sublineage of Streptococcus pyogenes in Germany, 2015-2023.Emerging microbes & infections · 2025Article
- Streptococcal Toxic Shock Syndrome Following Intestinal Obstruction in a Patient With Crohn's Disease.Cureus · 2025Article
- Article
- Restoring life expectancy in low-income countries: the combined impact of COVID-19, health expenditure, GDP, and child mortality.BMC public health · 2025Article
- Molecular and Clinical Characterization of InvasivePathogens (Basel, Switzerland) · 2025Article
- Post-pandemic upsurge of group A streptococcus infections: potential link to impaired herd trained immunity following COVID-19 lockdowns.Frontiers in immunology · 2025Article
- Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSince winter 2022, invasive GAS (iGAS) infections have re-emerged in Europe, causing severe diseases in children and adults. We aimed to examine whether this reported post-pandemic increase was associated with an increased disease severity and/or a shift in clinical disease phenotypes.
methodsWe performed detailed clinical phenotyping of patients hospitalized with iGAS infections at a 1410-bed tertiary German Medical Center from 01/2015 to 09/2023.
resultsOne hundred seventy-eight patients were included: 50 children (28.1%) and 128 adults (71.9%). IGAS infections of Q1/2023 exceeded the pre-pandemic average by 551% (1200% for children). The mean age of affected patients shifted significantly post-pandemically (49.5 ± 26.5 to 32.4 ± 28.2 years of age, p < 0.05), mainly due to the higher percentage of children affected with iGAS infections (15.2% pre-pandemic, 44.2% post-pandemic). CFR was significantly lower for children (2%) compared to adults (11.7%) (p < 0.05) and decreased from 13% to 6.5% post-pandemically (p = 0.148). Duration of antibiotic therapy (13.5 (10 to 21) to 10 (9 to 14) days), length of hospital (10 (4 to 25) to 7 (5 to 15) days), and ICU stay (7.0 (2.5 to 18.0) to 5.0 (3.0 to 8.5) days) were shorter post-pandemically. Despite the higher post-pandemic percentage of affected children, PICU admissions (57% before to 32% after), use of catecholamines (28.6% to 11.8%), invasive ventilation (35.7% to 17.6%) and CFR (7% to 0%) were all lower after the pandemic.
conclusionChildren were at higher risk for iGAS infections post-pandemically. The surge of post-pandemic iGAS infections was not accompanied by increased iGAS-associated morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.